Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-28
1998-04-14
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514284, 514253, 544296, 544316, 544333, 544405, 544407, 546 77, 546 78, 546 14, A61K 3158
Patent
active
057391378
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention provides novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the selective inhibition of the isozyme 5.alpha.-reductase 1.
BACKGROUND OF THE INVENTION
Certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, androgenetic alopecia which includes female and male pattern baldness, and benign prostatic hyperplasia, are the result of hyper-androgenic stimulation caused by an excessive accumulation of testosterone ("T") or similar androgenic hormones in the metabolic system. Early attempts to provide a chemotherapeutic agent to counter the undesirable results of hyperandrogenicity resulted in the discovery of several steroidal antiandrogens having undesirable hormonal activities of their own. The estrogens, for example, not only counteract the effect of the androgens but have a feminizing effect as well. Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethylisobutyranilide. See Neri, et al., Endocrinol. 1972, 91 (2). However, these products, though devoid of hormonal effects, compete with all natural androgens for receptor sites, and hence have a tendency to feminize a male host or the male fetus of a female host and/or initiate feed-back effects which would cause hyperstimulation of the testes.
The principal mediator of androgenic activity in some target organs, e.g., the prostate, is 5.alpha.-dihydrotestosterone ("DHT"), formed locally in the target organ by the action of testosterone-5.alpha.-reductase (or simply 5.alpha.-reductase). Inhibitors of 5.alpha.-reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation in these organs. See especially U.S. Pat. Nos. 4,377,584, issued Mar. 22, 1983, and 4,760,071, issued Jul. 26, 1988, both assigned to Merck & Co., Inc. It is now known that a second 5.alpha.-reductase isozyme exists, which interacts with skin tissues, especially in scalp tissues. See, e.g., G. Harris, et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 10787-10791 (November 1992). The isozyme that principally interacts in skin tissues is conventionally designated as 5.alpha.-reductase 1 (or 5.alpha.-reductase type 1), while the isozyme that principally interacts within the prostatic tissues is designated as 5.alpha.-reductase 2 (or 5.alpha.-reductase type 2).
In the treatment of androgenic sensitive disease conditions, e.g., benign prostatic hyperplasia (BPH) and/or the prevention and treatment of prostatic cancer, it would be desirable to have one drug entity which is active against both isozymes in the prostate to significantly inhibit all dihydrotestosterone production. It would also be desirable to have another drug entity which is highly selective for inhibiting the isozyme 5.alpha.-reductase 1 associated with the scalp, for use in treating conditions of the skin and scalp, e.g., acne vulgaris, male pattern baldness and hirsutism in females. Additionally, a selective 5.alpha.-reductase 1 inhibitor could be used in combination with a 5.alpha.-reductase 2 inhibitor such as, e.g., finasteride (PROSCAR.RTM.), for therapy in the treatment of hyperandrogenic conditions such as BPH and/or the prevention and treatment of prostatic cancer, and for the treatment of skin and scalp-related disorders such as acne vulgaris, seborrhea, female hirsutism, and androgenic alopecia. Still further, the 5.alpha.-reductase 1 inhibitors of this invention could be used in combination with a potassium channel opener such as minoxidil for the treatment of these skin and scalp-related disorders. Therefore it is an object of this invention to provide compounds that have sufficient activity in the inhibition of 5.alpha.-reductase isozyme 1.
SUMMARY OF THE INVENTION
The novel compounds of this invention have the formula ##STR2## and are selective 5.alpha.-reductase 1 inhibitors. It is an object of this invention to p
REFERENCES:
patent: 4220775 (1980-09-01), Rasmusson et al.
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 4859681 (1989-08-01), Rasmusson et al.
patent: 5049562 (1991-09-01), Rasmusson et al.
patent: 5084574 (1992-01-01), Bhattacharya et al.
patent: 5116983 (1992-05-01), Bhattacharya et al.
patent: 5120742 (1992-06-01), Rasmusson et al.
patent: 5138063 (1992-08-01), Rasmusson et al.
patent: 5151429 (1992-09-01), Rasmusson et al.
patent: 5215894 (1993-06-01), Arison et al.
patent: 5278159 (1994-01-01), Bakshi et al.
patent: 5407944 (1995-04-01), Goldman
patent: 5512555 (1996-04-01), Waldstreicher
patent: 5543417 (1996-08-01), Waldstreicher
patent: 5547957 (1996-08-01), Gormley et al.
patent: 5567708 (1996-10-01), Rasmusson et al.
Helliker, Wall Street Journal, Jun. 7, 1991, at A1, A7, "Alopecia Sufferers Seek to Suffer Less and Not in Silence".
Burger, Medicinal Chemistry, 2nd ed., (1960), p. 42, "Relation of Chemical Structure and Biological Activity".
Stinson, Chem. & Eng. News, pp. 7-8, Jun. 29, 1992, "Prostate Drug Proscar Cleared for Marketing".
Diani et al., J. Clin. Endocrin. & Metab., vol. 74, No. 2, pp. 345-350 (1990), "Hair Growth Effects of Oral Administration of Finasteride, a Steroid 5alpha-Reductase Inhibitor . . . ".
Rasmusson et al., J. Med. Chem., vol. 29, pp. 2298-2315 (1986), "Azasteroids: Structure Activity Relationship of Inhibiting 5alpha-Reductase and of Androgen Receptor Binding".
Walsh, The New England Journal of Medicine, "Treatment of Benign Prostatic Hyperplasia", vol. 335, No. 8 (Aug. 1996) pp. 586-587.
Boyle et al., Urology, Prostate Volume Predicts Outcome of Treatment of Benign Prostatic Hyperplasia with Finasteride: Meta-Analysis of Randomized Clinical Trials, vol. 48, No. 3, Sep. 1996, pp. 398-405.
The Daily, (Merck & Co., Inc.), Tuesday, May 7, 1996.
Lepor et al., The New England Journal of Medicine, The Efficacy of Terazoxin, Finasteride, or Both in Benign Prostatic Hyperplasia, vol. 335, No. 8 (Aug. 1996) pp. 533-539.
Hellicker, Wall St. Jour, 7 Jun. 1991 pp. A1, A7.
Stinson, Chem & Eng News 29 Jun. 1992 pp. 7,8.
Durette Philippe L.
Hagmann William K.
Langen Derek Von
Lanza, Jr. Thomas J.
Rasmusson Gary H.
Daus Donald G.
Fitch Catherine D.
Merck & Co. , Inc.
Nicholson William H.
Winokur Melvin
LandOfFree
16-substituted-4-aza-3-oxo-androstane as 5-alpha-reductase isozy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 16-substituted-4-aza-3-oxo-androstane as 5-alpha-reductase isozy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 16-substituted-4-aza-3-oxo-androstane as 5-alpha-reductase isozy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-634830